
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4675860/publications.pdf Version: 2024-02-01



ΔΙ ΔΛΝΛ Ρ ΟΗΠΚΙΛ

#	Article	IF	CITATIONS
1	Longâ€ŧerm weight loss maintenance with obesity pharmacotherapy: A retrospective cohort study. Obesity Science and Practice, 2022, 8, 320-327.	1.9	10
2	Weight Loss Outcomes With Telemedicine During COVID-19. Frontiers in Endocrinology, 2022, 13, 793290.	3.5	6
3	Literature review on antiobesity medication use for metabolic and bariatric surgery patients from the American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. Surgery for Obesity and Related Diseases, 2022, 18, 1109-1119.	1.2	9
4	Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty. Gastrointestinal Endoscopy, 2021, 93, 1110-1118.	1.0	45
5	Use of Weight Loss Medications in Patients after Bariatric Surgery. Current Obesity Reports, 2021, 10, 81-89.	8.4	29
6	Metformin-induced weight loss in patients with or without type 2 diabetes/prediabetes: A retrospective cohort study. Obesity Research and Clinical Practice, 2021, 15, 64-68.	1.8	19
7	An update on pharmacotherapeutic strategies for obesity. Expert Opinion on Pharmacotherapy, 2021, 22, 1305-1318.	1.8	6
8	The Independent Risk of Obesity and Diabetes and Their Interaction in COVIDâ€19: A Retrospective Cohort Study. Obesity, 2021, 29, 971-975.	3.0	17
9	Preadmission predictors of severe COVID-19 in patients with diabetes mellitus. Journal of Diabetes and Its Complications, 2021, 35, 107967.	2.3	6
10	Five-Year Outcomes of Endoscopic Sleeve Gastroplasty for the Treatment of Obesity. Clinical Gastroenterology and Hepatology, 2021, 19, 1051-1057.e2.	4.4	72
11	Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults. Expert Opinion on Pharmacotherapy, 2021, 22, 1-22.	1.8	2
12	Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2. Cell Metabolism, 2021, 33, 2174-2188.e5.	16.2	127
13	An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity. Expert Opinion on Pharmacotherapy, 2020, 21, 21-28.	1.8	9
14	Trial of restarting and tolerating metformin ( <scp>TreatMet</scp> ). Diabetes, Obesity and Metabolism, 2020, 22, 2189-2192.	4.4	4
15	Medical Weight‣oss Outcomes in Patients Receiving Concomitant Psychotropic Medication: A Retrospective Cohort Study. Obesity, 2020, 28, 1671-1677.	3.0	3
16	Utility of BMIQ, a novel webâ€based weight management programme, at an academic weight management centre. Obesity Science and Practice, 2020, 6, 134-138.	1.9	5
17	The impact of food order on postprandial glycaemic excursions in prediabetes. Diabetes, Obesity and Metabolism, 2019, 21, 377-381.	4.4	35
18	175 LONG-TERM FOLLOW UP AND OUTCOMES AFTER ENDOSCOPIC SLEEVE GASTROPLASTY FOR TREATMENT OF OBESITY (5 YEAR DATA). Gastrointestinal Endoscopy, 2019, 89, AB58.	1.0	18

#	Article	IF	CITATIONS
19	179 IMPROVEMENT IN NON-ALCOHOLIC FATTY LIVER DISEASE AFTER ENDOSCOPIC SLEEVE GASTROPLASTY. Gastrointestinal Endoscopy, 2019, 89, AB60-AB61.	1.0	2
20	Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial. Surgery for Obesity and Related Diseases, 2019, 15, 1348-1354.	1.2	40
21	Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options. Expert Opinion on Pharmacotherapy, 2019, 20, 585-593.	1.8	11
22	Current concepts in management of weight regain following bariatric surgery. Expert Review of Endocrinology and Metabolism, 2018, 13, 67-76.	2.4	32
23	Effect of Food Order on Ghrelin Suppression. Diabetes Care, 2018, 41, e76-e77.	8.6	11
24	The challenge of meeting prescribed carbohydrate intake goals in low-carbohydrate diet studies. American Journal of Clinical Nutrition, 2018, 107, 673-674.	4.7	2
25	Intestinal and Gastric Origins for Diabetes Resolution After Bariatric Surgery. Current Obesity Reports, 2018, 7, 139-146.	8.4	9
26	Pharmacotherapy for obesity in individuals with type 2 diabetes. Expert Opinion on Pharmacotherapy, 2018, 19, 223-231.	1.8	15
27	A single-operator learning curve analysis for the endoscopic sleeve gastroplasty. Gastrointestinal Endoscopy, 2018, 87, 442-447.	1.0	71
28	Endoscopic Sleeve Gastroplasty, Laparoscopic Sleeve Gastrectomy, and Laparoscopic Band for Weight Loss: How Do They Compare?. Journal of Gastrointestinal Surgery, 2018, 22, 267-273.	1.7	91
29	Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 315-320.	2.3	11
30	Resistance Training Reduces Skeletal Muscle Work Efficiency in Weightâ€Reduced and Non–Weightâ€Reduced Subjects. Obesity, 2018, 26, 1576-1583.	3.0	13
31	Weight Loss Medications in Older Adults After Bariatric Surgery for Weight Regain or Inadequate Weight Loss: A Multicenter Study. Bariatric Surgical Patient Care, 2018, 13, 171-178.	0.5	20
32	Weight Loss Medications in Young Adults after Bariatric Surgery for Weight Regain or Inadequate Weight Loss: A Multi-Center Study. Children, 2018, 5, 116.	1.5	34
33	Weight-Centric Management of Type 2 Diabetes Mellitus. Diabetes, 2018, 67, .	0.6	0
34	Obesity: When to consider surgery. Journal of Family Practice, 2018, 67, 614;616;618;620.	0.2	1
35	Endoscopic Sleeve Gastroplasty for Obesity: a Multicenter Study of 248 Patients with 24ÂMonths Follow-Up. Obesity Surgery, 2017, 27, 2649-2655.	2.1	194
36	Bariatric Surgery or Intensive Medical Therapy for Diabetes after 5 Years. New England Journal of Medicine, 2017, 376, 1995-1997.	27.0	29

#	Article	IF	CITATIONS
37	Percutaneous Gastrostomy Device for the Treatment of Class II and Class III Obesity: Results of a Randomized Controlled Trial. American Journal of Gastroenterology, 2017, 112, 447-457.	0.4	146
38	Endoscopic Sleeve Gastroplasty Significantly Reduces Body Mass Index and Metabolic Complications in Obese Patients. Clinical Gastroenterology and Hepatology, 2017, 15, 504-510.	4.4	182
39	Carbohydrate-last meal pattern lowers postprandial glucose and insulin excursions in type 2 diabetes. BMJ Open Diabetes Research and Care, 2017, 5, e000440.	2.8	43
40	A Cost-Utility Analysis Comparing Endoscopic, Surgical and Lifestyle Management of Obesity. Gastroenterology, 2017, 152, S831-S832.	1.3	1
41	Endoscopic Sleeve Gastroplasty, Laparoscopic Sleeve Gastroplasty, and Laparoscopic Band for Weight Loss, How do they Compare?. Gastroenterology, 2017, 152, S1209.	1.3	2
42	Is Obesity the New Hypertension? Parallels in the Evolution of Obesity and Hypertension as Recognized Disease States. Current Atherosclerosis Reports, 2017, 19, 35.	4.8	5
43	The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study. Surgery for Obesity and Related Diseases, 2017, 13, 491-500.	1.2	153
44	381 The AspireAssist Is an Effective Tool in the Treatment of Class II and Class III Obesity: Results of a One-Year Clinical Trial. Gastroenterology, 2016, 150, S86.	1.3	20
45	Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and <scp>SGLT</scp> 2s. Obesity, 2016, 24, 1955-1961.	3.0	91
46	Pharmacotherapy for Obesity. Endocrinology and Metabolism Clinics of North America, 2016, 45, 521-538.	3.2	28
47	101 Endoscopic Sleeve Gastroplasty for Obesity: A Multicenter Study of 242 Patients With 18 Months Follow-Up. Gastroenterology, 2016, 150, S26.	1.3	28
48	Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity. Expert Review of Clinical Pharmacology, 2016, 9, 27-34.	3.1	12
49	Drug-induced weight gain: Rethinking our choices. Journal of Family Practice, 2016, 65, 780-788.	0.2	10
50	Response to Comment on Shukla et al. Food Order Has a Significant Impact on Postprandial Glucose and Insulin Levels. Diabetes Care 2015;38:e98–e99. Diabetes Care, 2015, 38, e197-e197.	8.6	0
51	Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives. Expert Opinion on Biological Therapy, 2015, 15, 1061-1075.	3.1	20
52	Initial experience with endoscopic sleeve gastroplasty: technical success and reproducibility in the bariatric population. Endoscopy, 2015, 47, 164-166.	1.8	101
53	Food Order Has a Significant Impact on Postprandial Glucose and Insulin Levels. Diabetes Care, 2015, 38, e98-e99.	8.6	61
54	Treatment of Obesity in 2015. Journal of Cardiopulmonary Rehabilitation and Prevention, 2015, 35, 81-92.	2.1	42

#	Article	IF	CITATIONS
55	Lorcaserin Hcl for the treatment of obesity. Expert Opinion on Pharmacotherapy, 2015, 16, 2531-2538.	1.8	25
56	Refractory Hyperglycemia After Gastric Bypass Surgery: A Novel Subtype of Type 2 Diabetes?. Diabetes Care, 2014, 37, e254-e255.	8.6	8
57	Bariatric, Metabolic, and Diabetes Surgery. Annals of Surgery, 2014, 259, 117-122.	4.2	65
58	Surgical control of obesity and diabetes: The role of intestinal vs. gastric mechanisms in the regulation of body weight and glucose homeostasis. Obesity, 2014, 22, 159-169.	3.0	40
59	Initial Experience With Endoscopic Sleeve Gastroplasty Feasibility and Reproducibility of Technique. American Journal of Gastroenterology, 2014, 109, S571-S572.	0.4	0
60	Medical versus surgical treatment of type 2 diabetes: the search for level 1 evidence. Surgery for Obesity and Related Diseases, 2012, 8, 476-482.	1.2	16
61	Interventional Diabetology: The Evolution of Diabetes Care in the XXI Century. Current Atherosclerosis Reports, 2012, 14, 631-636.	4.8	1
62	Secretion and Function of Gastrointestinal Hormones after Bariatric Surgery: Their Role in Type 2 Diabetes. Canadian Journal of Diabetes, 2011, 35, 115-122.	0.8	9
63	Surgical treatment of type 2 diabetes: the surgeon perspective. Endocrine, 2011, 40, 151-161.	2.3	19
64	Medical weight management protects against weight gain during the COVIDâ€19 pandemic. Obesity Science and Practice, 0, , .	1.9	0